Redigerer Novavax COVID-19-vaksine (avsnitt)

== Utvikling ==
I januar 2020 kunngjorde Novavax utviklingen av en vaksinekandidat, kodet NVX-CoV2373, for å etablere immunitet mot [[SARS-CoV-2]].<ref name="gilgore">{{cite news | vauthors = Gilgore S |title=Novavax is working to advance a potential coronavirus vaccine. So are competitors. |url=https://www.bizjournals.com/washington/news/2020/02/26/novavax-is-moving-forward-with-a.html |work=Washington Business Journal |access-date=6. mars 2020 |date=26. februar 2020 |archive-date=16. mars 2020 |archive-url=https://web.archive.org/web/20200316041227/https://www.bizjournals.com/washington/news/2020/02/26/novavax-is-moving-forward-with-a.html |url-status=live }}</ref> Også mange andre vaksineprodusenter satte seg dette fore.<ref name="milken">{{cite web |title=COVID-19 vaccine tracker (click on 'Vaccines' tab) |url=https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/htmlview?pru=AAABchldaXU*ZWdU7a75RG6u_cw8QpEBhw# |publisher=Milken Institute |access-date=12. mai 2020 |date=11. mai 2020 |lay-url=https://milkeninstitute.org/covid-19-tracker |archive-date=6. juni 2020 |archive-url=https://web.archive.org/web/20200606220149/https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/htmlview?pru=AAABchldaXU*ZWdU7a75RG6u_cw8QpEBhw |url-status=live }}</ref> I mars 2020 bekjentgjorde Novavax at de samarbeidet med [[Emergent BioSolutions]] for preklinisk og tidligfases utprøving på mennesker.<ref>{{cite news|url=https://www.bizjournals.com/washington/news/2020/03/10/novavax-s-coronavirus-vaccine-program-is-getting.html|title=Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions| vauthors = Gilgore S |date=10. mars 2020|work=Washington Business Journal|access-date=10. mars 2020|archive-date=9. april 2020|archive-url=https://web.archive.org/web/20200409200636/https://www.bizjournals.com/washington/news/2020/03/10/novavax-s-coronavirus-vaccine-program-is-getting.html|url-status=live}}</ref> [[Emergent BioSolutions]] skulle produsere vaksinen i stor skala i sitt anlegg i [[Baltimore]].<ref>{{cite web | vauthors = McCartney R |title=Maryland plays an outsized role in worldwide hunt for a coronavirus vaccine|url=https://www.washingtonpost.com/local/maryland-plays-an-outsized-role-in-worldwide-hunt-for-a-coronavirus-vaccine/2020/05/03/3b6f2cb8-8bd5-11ea-8ac1-bfb250876b7a_story.html|website=Washington Post|url-status=live|archive-url=https://web.archive.org/web/20200507230732/https://www.washingtonpost.com/local/maryland-plays-an-outsized-role-in-worldwide-hunt-for-a-coronavirus-vaccine/2020/05/03/3b6f2cb8-8bd5-11ea-8ac1-bfb250876b7a_story.html|archive-date=7. mai 2020|access-date=8. mai 2020}}</ref>  Det ble også foretatt forsøk i [[Storbritannia]], og der ville man eventuelt produsere minst 60 millioner doser av [[Fujifilm Diosynth Biotechnologies]] i [[Billingham]].<ref name=guardian-20210128>{{cite news |url=https://www.theguardian.com/society/2021/jan/28/novavax-covid-vaccine-shown-to-be-nearly-90-effective-in-uk-trial |title=Novavax Covid vaccine shown to be nearly 90% effective in UK trial | vauthors = Boseley S, Davis N |newspaper=The Guardian |date=28. januar 2021 |access-date=29. januar 2021}}</ref><ref name=teesidelive-20200814>{{cite news |url=https://www.gazettelive.co.uk/news/teesside-news/60m-doses-new-covid-19-18767512 |title=60m doses of new covid-19 vaccine could be made in Billingham – and be ready for mid-2021 | vauthors = Brown M |website=TeesideLive |publisher=Reach |date=14. august 2020 |access-date=29. januar 2021}}</ref> Man inngikk også avtale med [[Serum Institute of India]] for masseproduksjon for utvikling og for forsyning av lavinnkomstland.<ref>{{cite news |title=Novavax signs COVID-19 vaccine supply deal with India's Serum Institute |url=https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-signs-covid-19-vaccine-supply-deal-with-indias-serum-institute-idINKCN25139A |work=Reuters |date=5. august 2020 }}</ref> Lignende produksjonsavtaler kom istand for Spania<ref>{{cite web | title = Spain, again chosen to produce the vaccine to combat COVID-19 | date = 18. september 2020 | url = https://www.thisistherealspain.com/en/latest-news/spain-again-chosen-to-produce-the-vaccine-to-combat-covid-19/ | work = This is the Real Spain | access-date = 2021-04-01 | archive-date = 2021-03-19 | archive-url = https://web.archive.org/web/20210319015957/https://www.thisistherealspain.com/en/latest-news/spain-again-chosen-to-produce-the-vaccine-to-combat-covid-19/ | url-status = yes }}</ref> og Polen, hos selskapet [[Mabion]].<ref>{{cite web | title = Novavax Deal With Mabion Boosts Poland’s Nascent Biotech Scene | date = 25. mars 2021 | url = https://www.bloomberg.com/news/articles/2021-03-03/novavax-deal-with-mabion-boosts-poland-s-nascent-biotech-scene | work = Bloomberg }}</ref>

De første studier om sikkerhet for mennesker begynte i mai 2020 i Australia.<ref name=fp>{{cite news|title=Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work| vauthors = Sagonowsky E |url=https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work|work=FiercePharma|date=11. mai 2020|access-date=12. mai 2020|archive-date=16. mai 2020|archive-url=https://web.archive.org/web/20200516215744/https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work|url-status=live}}</ref><ref>{{cite web|title=Novavax starts clinical trial of its coronavirus vaccine candidate|url=https://www.cnbc.com/2020/05/25/novavax-starts-phase-1-clinical-trial-of-coronavirus-vaccine-candidate.html|date=25. mai 2020 |publisher=CNBC |access-date=26. mai 2020|archive-date=26. mai 2020|archive-url=https://web.archive.org/web/20200526013622/https://www.cnbc.com/2020/05/25/novavax-starts-phase-1-clinical-trial-of-coronavirus-vaccine-candidate.html|url-status=live}}</ref>

I juli 2020 sa selskapet at det kanskje fikk $1,6 milliarder dollar fra [[Operation Warp Speed]] i USA for å aksellere utviklingen hvis de kliniske forsøkene var lovende nok.<ref name=":0">{{cite news| vauthors = Steenhuysen J |date=7. juli 2020|title=U.S. government awards Novavax $1.6 billion for coronavirus vaccine|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-novavax-idUSKBN248182|access-date=15. september 2020|archive-date=14. september 2020|archive-url=https://web.archive.org/web/20200914213046/https://www.reuters.com/article/us-health-coronavirus-novavax-idUSKBN248182|url-status=live}}</ref> I desember 2020 innledet Novavax Fase III-utprøving i USA og Mexico.<ref>{{cite web | title=Phase 3 trial of Novavax investigational COVID-19 vaccine opens | website=National Institutes of Health (NIH) | date=28. desember 2020 | url=https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens | access-date=28. desember 2020 }}</ref>

Den 28. januar 2021 meldte Novavax foreløpige resultater for den britiske utprøving; vaksinekandidaten var over 89% effektiv.<ref name="BBC 20210108">{{cite news|date=28. januar 2021|title=New Covid vaccine shows 89% efficacy in UK trials|work=BBC News|url=https://www.bbc.com/news/uk-55850352|access-date=28 January 2021}}</ref><ref>{{cite news| vauthors = Lovelace B |date=28. januar 2020|title=Novavax says Covid vaccine is more than 89% effective|work=CNBC|url=https://www.cnbc.com/2021/01/28/covid-vaccine-novavax-says-covid-vaccine-is-more-than-89percent-effective.html}}</ref> Men interimresultater fra Sør-Afrika viste en lavere effektivitet mot [[501.V2-varianten]] av viruset: Rundt 50–60%.<ref name="doi 10.1126/science.abg8101">{{cite journal | vauthors = Wadman M, Jon C | title=Novavax vaccine delivers 89% efficacy against COVID-19 in UK—but is less potent in South Africa | journal=Science | date=28. januar 2021 | doi=10.1126/science.abg8101 | doi-access=free }}</ref><ref>{{cite web | vauthors = Facher L, Joseph A | title=Novavax says its Covid-19 vaccine is 90% effective in late-stage trial | website=[[Stat (website)|Stat]] | date=28. januar 2021 | url=https://www.statnews.com/2021/01/28/novavax-says-its-covid-19-vaccine-is-90-effective-but-far-less-so-against-one-variant/ | access-date=29. januar 2021 }}</ref> Den 12. mars 2021 meldte Novavax at deres vaksinekandidat var 96,4% effektiv mot den opprinnelige formen av [[covid-19]] og 86% effektiv mot [[Lineage B.1.1.7]]. Den var 55% effektiv mot [[501.V2-varianten]] i mennesker uten [[HIV/AIDS]]. Den var også 100% effektiv hva gjaldt særlig alvorlig sykdomsforløp.<ref>{{Cite news|last=O’Donnell|first=Carl|last2=Nadeem|first2=Dania|date=11. mars 2021|title=Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial|work=Reuters|url=https://www.reuters.com/article/uk-health-coronavirus-vaccines-novavax-idUSKBN2B32ZI|access-date=23. mars 2021}}</ref>